EDESA BIOTECH, INC. Impairment of Intangible Assets, Finite-lived
EDESA BIOTECH, INC. (EDSA) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2016-09-30, per its 10-K filed 2016-12-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2016-12-14
- EDESA BIOTECH, INC. impairment of intangible assets, finite-lived for fiscal 2016 was $0.00.
- EDESA BIOTECH, INC. impairment of intangible assets, finite-lived for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- EDESA BIOTECH, INC. impairment of intangible assets, finite-lived for fiscal 2014 was $90.48K.
- EDESA BIOTECH, INC. impairment of intangible assets, finite-lived for fiscal 2013 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 1 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|
| 2016-09-30 | $0.00 10-K · filed 2016-12-14 | |
| 2015-09-30 | $0.00 10-K · filed 2016-12-14 | |
| 2014-09-30 | $0.00 10-K · filed 2016-12-14 | |
| 2014-08-31 | $90.48K 10-K · filed 2016-12-14 | |
| 2013-08-31 | $0.00 10-K · filed 2014-11-21 | |
| 2012-08-31 | $0.00 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |